Product

Ipilimumab+Nivolumab

1 clinical trial

1 indication

Indication

Metastatic Melanoma

Clinical trial

Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden: An Observational Study

Status: Completed, Estimated PCD: 2021-12-03